Innovation
Inven2 are responsible for assessing and commercialising innovative research conducted at the University of Oslo, Oslo University Hospital and the health trusts under the South-Eastern Norway Regional Health Authority.
Since the establishment of Inven2 ten years ago, we have contributed to the establishment of 55 companies and 388 licenses alongside innovative researchers. This has led to NOK 500 million being channelled back to research and innovation.
Innovation motivated by patients
Jan Terje Andersen learnt about laboratory work when he was studying to become a biomedical laboratory scientist. Scientific curiosity led him to the Department of Biosciences at the University of Oslo.
A lecture by Professor Inger Sandlie decided his future career. Today, he is one of the researchers with the most innovations at Inven2.
Information
Portfolio businesses
More businesses
Portfolio businesses
Inven2 has a portfolio comprising 53 companies. We have established them either on our own or alongside investors to commercialise research results from innovative researchers. The point of departure for the companies are research results from innovative researchers. The portfolio value in October 2020 is NOK 23 billion, but this will vary with the value of the individual company and how long we are shareholders in the most valuable companies.
Products on the market
More products
Products on the market
Inven2 has contributed to many products and services that have served society well through licensing to industry or business start-ups within a range of technology fields. What follows is a selection of them.
EPISHUTTLE – Transport isolator
Photo: EpiGuard
QUEST 5 HMC DNA ELISA KIT Epigenetic kit
Photo: Zymo Research
PROBNP – Heart disease test
Photo: Roche
Latest innovation news
More news
Latest innovation news
These are news about Inven2’s new and ongoing innovation projects, companies we have been a contributed part in establishing, new products and services on the market and other relevant news regarding innovation.
Will revolutionise CAR-T therapy with a Norwegian licence
In April 2021, the Dutch company CellPoint in-licensed a CD37 CAR from Inven2. It is a kind of cell therapy for treating blood cancer developed by...
Vital licences
Inven2 has long experience of licence agreements, particularly in life sciences, which dominate the portfolio. The available licences are presented...
A unique biological super-taxi has been developed
Most protein-based therapeutics must be injected to be effective. That is both stressful for the patient and costly for the healthcare system....
